Ask AI

Empowering Oncology Nurses in HER2-Positive GEA and BTC: Practical Strategies for Safe and Effective Targeted Therapy Management

Video
This activity is available for 0.75 CME/CE credit(s).

Released: October 20, 2026

Expiration: April 19, 2027

See Activity Collection

In this on-demand webcast, an expert reviews the evolving role of HER2-targeted therapies in gastroesophageal adenocarcinoma and biliary tract cancer, emphasizing the importance of biomarker testing, treatment selection, and proactive toxicity management. Clinical trial evidence supporting established and emerging HER2-directed treatment strategies, including trastuzumab-based regimens, zanidatamab, and trastuzumab deruxtecan, is discussed, along with their efficacy, safety profiles, and implications for treatment sequencing. Key considerations include HER2 testing and reassessment at disease progression, recognition and management of treatment-related adverse events such as infusion-related reactions, diarrhea, and interstitial lung disease/pneumonitis, and strategies for patient education and symptom triage. The faculty also highlights the role of oncology nurses in multidisciplinary care coordination, shared decision-making, and early intervention to support treatment tolerability and optimize patient outcomes.

HER2pos GEA and BTC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with gastroesophageal adenocarcinoma or biliary tract cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which statement best reflects the HERIZON-GEA-01 findings and their potential implications for nursing practice in HER2-positive GEA?

4.

A patient is starting zanidatamab for previously treated HER2-positive IHC 3+ BTC. Which nursing action is most appropriate before the first infusion?

5.

A patient with HER2-positive GEA has disease progression after trastuzumab-based therapy. The patient asks whether another biopsy or HER2 test may be needed. Which response best supports patient education and coordinated care?